FOLR1 Antibody, HRP conjugated

1. This research highlights a novel approach employing a combination of EpCAM and FRalpha as CTC-capture targets to enhance the sensitivity, specificity, and speed of CTC detection in NSCLC. PMID: 29352248
2. Multiple experimental studies in mice and human epidemiological and genetic investigations suggest that FOLR1 abnormalities contribute to a subset of human neural tube defects (NTD), although FOLR1 defects alone do not cause NTD. (Review) PMID: 28244241
3. FOLR1 is highly expressed in ovarian cancer but is reduced following multidrug resistance. It may serve as a valuable biomarker for ovarian cancer and could be leveraged to enhance sensitivity to cisplatin treatment. PMID: 29433550
4. Silencing of mTORC1 or mTORC2 significantly decreases the plasma membrane expression of FR-alpha and RFC transporter isoforms without affecting global protein expression. PMID: 27562465
5. High Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer. PMID: 28410844
6. The expression of folate receptor 1 (FOLR1) was significantly higher and more frequent in metastatic lymph node samples from patients with advanced lung cancer. PMID: 29110850
7. This study identified eight novel variants in SLC19A1 and twelve novel variants in FOLR1, FOLR2, and FOLR3. Pathogenic variants include c.1265delG in SLC19A1 resulting in a premature stop codon, four large insertion-deletion variants in FOLR3, and a stop-gain variant in FOLR3. PMID: 28948692
8. This study investigated the design of folate receptor alpha (FRa)-targeted nano-liposomes (FLP) to enhance the anti-tumor effect by targeting delivery of exogenous PEDF gene to cervical cancer cells. These results demonstrate the potential of FLP as carriers for PEDF gene and FLP/PEDF as a promising novel strategy for gene therapy of cervical cancer. PMID: 27576898
9. Data indicate that higher folate receptor alpha (FRalpha) expression is predictive of a favorable prognosis in pancreatic ductal adenocarcinoma (PDAC), suggesting FRalpha as a promising target for therapeutic interventions. PMID: 28430580
10. These findings highlight the substantial therapeutic potential of novel 6-substituted pyrrolo[2,3-d]pyrimidine antifolates with dual targeting of PCFT and FRalpha for the treatment of Epithelial ovarian cancer, particularly those expressing a range of FRalpha, along with PCFT, and exhibiting cisplatin resistance. PMID: 28138029
11. Low expression levels of FOLR1 are associated with neuroendocrine lung tumors. PMID: 27064343
12. Folr1 emerges as a potential predictive candidate and therapeutic target for medulloblastoma. PMID: 28416738
13. Folr1 is a favorable target for fluorescence-guided surgery, as the tumor-specific agent EC17 produces a clear fluorescent signal in ovarian and breast cancer tissue. PMID: 27014973
14. The Folate receptor alpha is associated with the progression of cervical cancer and regulates cervical cancer cells' growth through phosphorylating ERK1/2, c-Fos, and c-Jun, key factors in the ERK signaling pathway. PMID: 28782518
15. Folate receptor alpha protein was expressed in the majority of lung adenocarcinomas and a minority of lung squamous cell carcinomas. Folate receptor alpha protein expression correlated with histologic grade for lung adenocarcinomas, with the most notable difference observed between grade 1 and grade 3. PMID: 26599808
16. This study demonstrates the efficacy of silencing HuR in lung cancer cells using a folate-conjugated nanoparticle system that targets folate receptor-alpha overexpressing cancer cells. PMID: 27328938
17. This novel protocol provides an effective means to synthesize and design novel fluorescent nano-conjugates for FR expression investigation in tumor cells via targeted imaging, showing great potential in drug delivery mechanism studies and cancer therapy. PMID: 26606305
18. RNA interference-mediated suppression of FOLR1 altered the gene expression profile of taxol-resistant nasopharyngeal carcinoma cells. Apoptosis-related genes and gene alterations in viral carcinogenesis/MAPK pathways might be crucial for reversing taxol resistance. PMID: 26617855
19. This study confirmed similarities between epithelial ovarian cancer and fallopian tube, both normal and adenocarcinoma, using FOLR1, FOLR2, CD68, and CD11b markers. PMID: 25971554
20. This study suggests RNA CAR T cell therapy as a potential treatment for common epithelial cancers expressing folate receptor-alpha. PMID: 26359629
21. This study investigated the expression of folate receptors on murine and human adipose tissue macrophages. PMID: 26149693
22. These findings suggest the clinical development of IMGN853 as a novel targeted therapy for patients with folate receptor alpha (FRalpha)-expressing tumors. PMID: 25904506
23. This study suggests that FRalpha overexpression may play a role in the development of endometrioid endometrium carcinoma and its progression from endometrial hyperplasia. PMID: 26191275
24. Triple negative/basal tumors demonstrated a significant association with increased expression of FOLR1 mRNA compared to ER+ and HER2+ tumors. PMID: 25816016
25. This study conducted a molecular dynamic simulation of the binding process of folic acid to folate receptor alpha. PMID: 25323390
26. Studies indicate folate receptor (FR) as a prognostic biomarker for ovarian cancer. PMID: 25564455
27. The overexpression of folate receptor alpha mRNA was associated with the growth of pituitary adenomas. PMID: 26014017
28. This study is the first to simultaneously evaluate both DNA methylation and protein expression of all three folate transporter genes, FOLR1, PCFT, and RFC1, in colorectal cancer. PMID: 25697897
29. FRalpha down-regulation may suppress cervical cancer cell proliferation and promote apoptosis. PMID: 25081683
30. Survival times are improved in non-small-cell lung cancer patients whose tumors show strong membranous folate receptor alpha expression. PMID: 24993594
31. This study investigated the conditions associated with circulating FOLR1 protein in healthy individuals. PMID: 24810481
32. This research suggests that quantitation of CTCs through FRalpha ligand-PCR could be a promising noninvasive method for diagnosing bladder TCC. PMID: 24771263
33. 74% of ER/PR-negative and 80% of triple-negative breast cancers expressed folate receptor alpha (FRA). FRA expression was significantly associated with worse disease-free survival. PMID: 24028341
34. Expression of FOLR1 was significantly elevated in the serum of ovarian cancer patients compared to the serum of both healthy controls and patients with benign gynecological conditions. PMID: 23528302
35. FOLR1 expression was significantly higher in pituitary adenomas of patients older than 50 years. PMID: 23023342
36. The FRalpha gene was expressed in all parathyroid cells analyzed, and the FRbeta gene was expressed by most. PMID: 24206618
37. This study determined the crystal structure of human FRalpha in complex with folic acid at 2.8 A resolution. PMID: 23851396
38. These findings further support the hypothesis that folate receptor-alpha expression in gynecologic tumors is due to the cell of origin normally expressing this receptor. PMID: 23518909
39. EpCAM, FR-alpha, and VEGF-A are the most promising molecules for use in targeted intraoperative fluorescence imaging of endometriotic lesions due to their favorable expression patterns and biomarker characteristics. PMID: 23332132
40. Studies indicate that folate receptor alpha (FOLR1), a folate transporter, is an attractive target for cancer therapy due to its high affinity for folate, restricted expression in normal tissue, and differential overexpression in malignant tissue. PMID: 23357463
41. Overexpression of folate receptor alpha was associated with ovarian tumor progression. PMID: 23144806
42. The folate receptor alpha translocates to the nucleus, where it binds to cis-regulatory elements at promoter regions of Fgfr4 and Hes1, and regulates their expression. PMID: 23243496
43. A significant percentage of lung cancers, including squamous cell carcinomas in addition to adenocarcinomas, strongly express folate receptor alpha. PMID: 22984810
44. PCR analysis confirmed the existence of FR-alpha, SMVT, and B ((0, +)) in Y-79 and ARPE-19 cells. PMID: 22304562
45. High folate receptor alpha is associated with adenocarcinoma in non-small-cell lung carcinoma and EGFR mutation. PMID: 22729036
46. alpha-FR may serve as a potential biomarker for predicting chemotherapeutic responses and clinical prognosis. PMID: 22265591
47. Studies suggest that different clinical severities do not necessarily correlate with residual function of folate receptor alpha mutants. PMID: 22586289
48. FR-alpha was expressed in the majority of serous ovarian tumors, although over 50% of cases showed only weak expression. PMID: 21647742
49. FRalpha may play a crucial role in the development and progression of NFAs. PMID: 22089756
50. This study demonstrates an ancient double-mutated haplotype 1816delC-1841A in the FOLR1 gene. PMID: 21938430

Show More

Hide All

HGNC: 3791

OMIM: 136430

KEGG: hsa:2348

STRING: 9606.ENSP00000308137

UniGene: Hs.73769